IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Daclizumab for relapsing remitting multiple sclerosis
Liu, Jia1; Wang, Luning1; Zhan, Si-Yan2; Xia, Yinyin3
关键词Antibodies, Monoclonal [therapeutic use] Antibodies, Monoclonal, Humanized Immunoglobulin G [therapeutic use] Immuno-suppressive Agents [therapeutic use] Multiple Sclerosis, Relapsing-Remitting [drug therapy] Humans
刊名COCHRANE DATABASE OF SYSTEMATIC REVIEWS
2012
DOI10.1002/14651858.CD008127.pub3
4
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]DIAGNOSTIC-CRITERIA ; MONOCLONAL-ANTIBODY ; IN-VIVO ; CELLS ; GUIDELINES ; THERAPY
英文摘要

Background

The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.

Objectives

To assess the efficacy and safety of daclizumab for the clinical progression of patients with relapsing remitting multiple sclerosis.

Search methods

We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group′s Trials Register (February 2012), MEDLINE (January 1966 to February 2012), EMBASE (January 1985 to February 2012). At the same time, we handsearched the references quoted in the identified trials reports (February 2012) from the most important neurological associations and MS Societies. Contacts with researchers participating in trials on daclizumab have been established.

Selection criteria

All randomized controlled clinical trials (RCTs) evaluating daclizumab, alone or combined with other treatments versus placebo, or any other treatment for patients with RRMS.

Data collection and analysis

Two review authors independently assessed references retrieved for possible inclusion. Disagreements regarding inclusion were resolved by consensus. We contacted study authors for additional information. We collected adverse effects information from the trials.

Main results

We identified 470 references from all electronic databases searched excluding duplicate. After screening of titles and abstracts, full papers of 10 studies were obtained and assessed for eligibility. An additional ongoing trial was found. Only one trial (230 participants) evaluating the efficacy of daclizumab versus placebo in interferon beta treated patients was included. It was judged as of high quality study. No significant difference was found in the expanded disability score changes and the annualised relapse rate comparing treated versus placebo groups. No significant difference of common adverse events was found across all the groups at the endpoint. The mean number of new or enlarged gadolinium contrast-enhancing lesions was significantly decreased in the interferon beta and high-dose daclizumab group, compared with that in the interferon beta and placebo group.

Authors′ conclusions

Daclizumab is well tolerated in combination with interferon beta treated multiple sclerosis population. Comparing with placebo, high-dose daclizumab can significantly decreased the number of new or enlarged gadolinium contrast-enhancing lesions. However, the evidence of recommendation is insufficient. More well-designed RCTs or crossover controlled trials are required to evaluate the efficacy and safety of daclizumab.

语种英语
WOS记录号WOS:000303012500011
Citation statistics
Cited Times:3[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65750
Collection北京大学公共卫生学院
作者单位1.Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Neurol, Beijing 100853, Peoples R China
2.Peking Univ, Ctr Evidence Based Med & Clin Res, Dept Epidemiol & Biostat, Sch Publ Hlth, Beijing 100871, Peoples R China
3.China CDC, Dept Surveilance & Stat, Natl Ctr TB Control & Prevent, Beijing, Peoples R China
Recommended Citation
GB/T 7714
Liu, Jia,Wang, Luning,Zhan, Si-Yan,et al. Daclizumab for relapsing remitting multiple sclerosis[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2012(4).
APA Liu, Jia,Wang, Luning,Zhan, Si-Yan,&Xia, Yinyin.(2012).Daclizumab for relapsing remitting multiple sclerosis.COCHRANE DATABASE OF SYSTEMATIC REVIEWS(4).
MLA Liu, Jia,et al."Daclizumab for relapsing remitting multiple sclerosis".COCHRANE DATABASE OF SYSTEMATIC REVIEWS .4(2012).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Liu, Jia]'s Articles
[Wang, Luning]'s Articles
[Zhan, Si-Yan]'s Articles
百度学术
百度学术Similar articles in
[Liu, Jia]'s Articles
[Wang, Luning]'s Articles
[Zhan, Si-Yan]'s Articles
必应学术
必应学术Similar articles in
[Liu, Jia]'s Articles
[Wang, Luning]'s Articles
[Zhan, Si-Yan]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.